RealTime Dynamix™: Rheumatoid Arthritis Q2
RealTime Dynamix: Rheumatoid Arthritis Q2 is the second instalment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. The Q2 report contains constant trended content, including current and future patient share, barriers to growth, industry contact rates, awareness and familiarity with products in development and sources of […]
RealTime-Dynamix-Crohns-Disease-Q3
Building on the 2016 RealWorld Dynamix Report, which drew upon data from over 1000 CD patient charts and 200 Gastroenterologists, Spherix Global Insights are currently fielding the RealTime Dynamix research project with around 100 US gastroenterologists. RealTime Dynamix™: IBD provides a close-quarters overview of key performance metrics, focusing on brand gains and losses, industry contact […]
RealWorld Dynamix™: Biologic Switching Patterns in IBD Patient Power in Action
Spherix Global Insights collaborated with 211 practicing gastroenterologists in the US to analyze the medical records for over 1,000 patients with IBD who had recently been switched from one biologic to another. Patients are playing an increasing role in treatment decisions. About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and […]
Despite An Increase in Psoriatic Arthritis Patients Initiated on Cosentyx Over the Past Three Months, the User Base for Novartis’ IL-17 Inhibitor Has Remained Stable
Download Report Overview ZUG, Switzerland, Nov. 2, 2016 /PRNewswire/ — A recent study of nearly 100 surveyed US rheumatologists reveals that after approximately nine months on the market, not only are current users of Novartis’ Cosentyx reporting increased PsA initiations, but the brand has also made significant gains in biologic patient share. Despite increased overall […]
Direct to Consumer Campaigns for Pfizer’s Xeljanz, Abbvie’s Humira, and Amgen’s Enbrel the Most Influential with RA Patients
Despite the reported influence of DTC campaigns on RA patients, US rheumatologists doubt the effectiveness and appropriateness of brand advertising in RA, according to Spherix Global Insights Download Report Overview October 25, 2016 – Cambridge, Massachusetts. Survey responses of nearly 100 US rheumatologists reveal that RA patients are significantly more influenced by the DTC campaigns […]
Roche’s Ocrelizumab Expected To Introduce Major Shifts In The Treatment Paradigm For Multiple Sclerosis.
Spherix Global Insights releases the Q3 update for RealTime Dynamix™: Multiple Sclerosis based on survey responses from 104 US neurologists. Download Report Overview CAMBRIDGE, Mass., Oct. 11, 2016 — There is high anticipation for Roche’s ocrelizumab, a monoclonal antibody that was granted “Breakthrough Therapy Designation” by the FDA earlier this year for its potential indication in […]
RealTime Dynamix™: Crohn’s Disease US Q3 2016 Spotlight
RealTime Dynamix™: Crohn’s Disease Q3 Gastroenterologists poised to adopt Janssen’s recently approved Stelara (ustekinumab) for the treatment of Crohn’s disease RealTime Dynamix™: Crohn’s Disease Q3 is the first installment of a quarterly publication focusing on current and anticipated trends in the Crohn’s disease (CD) market. Analysis covers the major inline brands including Remicade, Humira, Entyvio, […]
Use Of Takeda’s Entyvio Fueled By Gastroenterologists Seeking Better Outcomes And Alternatives To AbbVie’s Humira And Janssen’s Remicade In The Treatment Of Crohn’s Disease
According to a recently released independent report from Spherix Global Insights there is high demand for alternative mechanism biologics and small molecules in the IBD arena ZUG, Switzerland, Sept. 23, 2016 — In a market long dominated by AbbVie’s Humira and Janssen’s Remicade, practice patterns are shifting and novel pipeline agents will introduce a new […]
Keryx’s Supply Interruption Of Auryxia And The Delayed Approval For Amgen’s Parsabiv Shake Things Up In The Renal Market
Download Report Overview ZUG, Switzerland, Sept. 20, 2016— While nephrologists are stating that the recent supply interruption of Keryx’s phosphate binder, Auryxia, does not have a major impact on their practice, the challenge for Keryx will be the re-build – 48% of the nephrologists that had patients on Auryxia, anticipate a slow uptake once supply […]
Eli Lilly’s Taltz And Novartis’ Cosentyx Introduce Disruption To The Psoriasis Market, According To A New Report From Spherix Global Insights
As the two IL-17s fight for differentiation, other biologics brace for share offsets, based on a recent survey of 99 US dermatologists. Download Report Overview ZUG, Switzerland, Sept. 19, 2016 — Over 70% of the surveyed dermatologists report that their biologic use has increased over the past year, playing catch up to rheumatologists’ use in […]
